Zinc-doped mesoporous silica nanoparticle antibacterial osteoinductive formulation and method of making same

By adding zinc precursors and surface modification in stages, zinc-doped mesoporous silica nanoparticles were prepared, which solved the problems of mismatch in zinc ion release and lack of synergy between antibacterial and bone-promoting functions, and achieved efficient drug loading and multifunctional synergistic effects of mesoporous silica nanoparticles in bone repair materials.

CN122624684APending Publication Date: 2026-08-25THE 1ST AFFILIATED HOSPITAL OF SHIHEZI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611045343.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-14
Publication Date
2026-08-25

AI Technical Summary

Technical Problem

Existing zinc-doped mesoporous silica nanoparticles in bone repair materials suffer from problems such as mismatch between zinc ion release and bone healing stage requirements, lack of synergy between antibacterial and bone-promoting functions, limited drug loading capacity, and uneven release.

Method used

Mesoporous silicon nanoparticles were prepared by template method, and zinc precursor was added in stages and subjected to heat treatment. Combined with surface modification and loading of active components, zinc-doped mesoporous silicon nanoparticles were constructed to achieve dispersion of zinc components in the framework, pore walls and surface layer, combined with mesoporous channel loading and surface end-capping structure.

Benefits of technology

It achieves the phased release of zinc ions and the efficient loading of antibacterial active substances, adapts to the multi-factor synergistic intervention in the bone defect repair process, and improves the functional adaptability and safety of the material.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122624684A_ABST
    Figure CN122624684A_ABST
Patent Text Reader

Abstract

This invention discloses an antibacterial and osteogenic formulation of zinc-doped mesoporous silica nanoparticles and its preparation method. A mesoporous silica precursor is prepared using a template method, and a zinc precursor is added in stages during the hydrolysis and condensation process of the silica source, ensuring uniform dispersion of the zinc component in the framework, pore walls, and surface layer. After heat treatment to remove the template, zinc-doped mesoporous silica nanoparticles (Zn-MSN) are obtained. Further surface modification with amylation, loading with antibacterial agents and / or osteogenic active components, and construction of an end-capping layer yield a multifunctional formulation. The formulation has an average particle size of 80–200 nm and a specific surface area of ​​150–350 m² / g. 2 / g, the zinc component has no independent crystalline phase, which can realize the time-sequential release of zinc ions and active components; in vitro experiments show that the formulation has an antibacterial rate of >99% against Staphylococcus aureus and other bacteria, and can significantly enhance ALP activity, mineralized nodule formation and RUNX2 / OCN expression, and has both antibacterial and osteopromoting synergistic effects, making it suitable for the repair of infected bone defects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of bone repair materials technology, specifically relating to an antibacterial and osteogenic preparation of zinc-doped mesoporous silicon nanoparticles and its preparation method. Background Technology

[0002] Bone defects are a common clinical outcome of trauma or disease, caused by factors such as injury, tumor resection, infection, and osteoporosis. The repair process is complex and lengthy. Bone healing typically involves three stages: inflammation, repair and mineralization, and bone remodeling. The local microenvironment differs significantly at each stage. The early inflammatory stage is often accompanied by local acidification, elevated inflammatory factors, and increased bacterial load, while the later mineralization stage requires continuous and stable osteogenic stimulation. Therefore, bone repair materials not only need to promote bone growth but also need to meet the stage-specific needs of bone healing, achieving a synergistic match between antibacterial, bone-promoting, and release behaviors.

[0003] Zinc (Zn) is one of the essential trace elements for bone tissue metabolism in the human body. It participates in the regulation of osteogenic-related signals, promotes osteoblast differentiation, alkaline phosphatase activation, and bone matrix mineralization, and has a certain inhibitory effect on osteoclast activity. However, the biological effects of zinc ions are significantly dose-dependent. Low concentrations promote cell proliferation and osteogenic differentiation, while excessively high local concentrations may have cytotoxic effects, leading to decreased osteogenic efficacy or even cell damage. Therefore, maintaining the release of zinc ions within an effective and safe therapeutic window is a key issue in the design of zinc-based bone repair materials.

[0004] Mesoporous silica nanoparticles (MSNs) are widely used in drug delivery and bone repair due to their large specific surface area, tunable pore size, easy surface modification, and good biocompatibility. Existing technologies have attempted to introduce zinc, in the form of zinc oxide or other forms, into silica-based materials to achieve sustained release of zinc ions and promote osteogenic effects. However, existing zinc-doped mesoporous silica systems still have the following shortcomings: First, zinc is often dispersed relatively uniformly in the material, lacking precise control over the distribution of zinc within the framework and on the pore wall surface, making it difficult to match the release kinetics to the bone healing stages; second, in the acidic environment of early bone repair, the zinc-phase key structure is more prone to hydrolysis, easily causing excessively rapid release of zinc ions during the inflammatory phase, forming local concentration peaks, leading to cytotoxicity and safety risks; third, existing methods often rely on external inorganic coatings or polymer encapsulation to reduce burst release and improve release curves, which not only involves complex preparation processes but also easily affects the openness of mesoporous channels and the overall reproducibility of the material.

[0005] Furthermore, in bone defects, especially infected bone defects or postoperative bone repair scenarios, in addition to the need for continuous zinc ion-induced osteogenic effects, materials often need to provide strong antibacterial activity in the early stages to inhibit bacterial adhesion, biofilm formation, and the spread of local infection. While existing mesoporous silica systems possess good drug loading potential, common drug loading methods mainly rely on physical adsorption or simple embedding, generally suffering from limited drug loading capacity, significant early burst release, and difficulty in achieving phased release of "early antibacterial, later osteogenic". If sustained release is achieved through additional end-capping, gating, or surface coating, it easily reduces the effective utilization rate of the mesoporous channels, weakening the high drug loading advantage, and makes it difficult to simultaneously achieve the synergistic release of antibacterial components and zinc ions. Therefore, existing technologies still present a significant contradiction between "high drug loading capacity" and "time-sequential release capability," and a structural design that can simultaneously achieve phased release of zinc ions and efficient loading of antibacterial active substances within a single nanoparticle is lacking.

[0006] Therefore, there is an urgent need in this field to develop a novel zinc-doped mesoporous silica nanoparticle antibacterial and osteogenic agent and its preparation method, so that the material can structurally combine sequential release of zinc ions, high drug loading capacity in mesoporous channels, and synergistic antibacterial and osteogenic functions, thereby better meeting the clinical needs of bone defect repair, especially the repair of infected bone defects.

[0007] The information disclosed in this background section is intended only to enhance the understanding of the overall background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art known to those skilled in the art. Summary of the Invention

[0008] To address the issues of inconsistent technologies, limited carrier functions, and incomplete loading systems in existing zinc-doped mesoporous silicon materials regarding structural construction, active component loading, and surface capping, this invention provides a preparation method based on mesoporous silicon nanoparticles. This method involves introducing zinc components in stages and further modifying the surface and loading active components, resulting in a formulation that possesses a zinc-doped structure, a pore-loaded structure, and a surface-capped structure.

[0009] To achieve the above objectives, the present invention adopts the following technical solution:

[0010] A method for preparing an antibacterial and osteopromoting agent using zinc-doped mesoporous silica nanoparticles includes the following steps:

[0011] 1) Mesoporous silica nanoparticle precursors were prepared using a template method;

[0012] 2) During the hydrolysis and condensation process of the silicon source, zinc precursor is added in stages to disperse the zinc component in the framework region and pore wall region of the mesoporous silicon particles.

[0013] 3) The obtained system was aged, centrifuged, collected, washed and dried to obtain zinc-doped mesoporous silicon precursor particles;

[0014] 4) The precursor particles are subjected to heat treatment to remove the template agent, thereby obtaining zinc-doped mesoporous silicon nanoparticles;

[0015] 5) The obtained particles were surface modified and loaded with active components to obtain a zinc-doped mesoporous silicon nanoparticle antibacterial and osteopromoting agent.

[0016] Preferably, the template agent in step 1) is hexadecyltrimethylammonium bromide, the silicon source is tetraethyl orthosilicate, the mass ratio of the template agent to tetraethyl orthosilicate is 1:8 to 1:12, the pH of the reaction system is 8.0 to 9.5, the reaction temperature is 60 to 80°C, and the stirring rate is 500 to 1000 rpm.

[0017] Preferably, in step 2), the first zinc precursor solution is added 30 to 45 minutes after the silicon source is added, and the second zinc precursor solution is added 60 to 90 minutes after the first zinc precursor solution is added.

[0018] Preferably, in step 2), the zinc component of the first zinc precursor solution accounts for 1 to 3 mol, and the addition of the second zinc precursor solution makes the total molar percentage of zinc component reach 4 to 8 mol.

[0019] Preferably, the zinc precursor is an alcoholic solution of zinc acetate and / or zinc nitrate, and the concentration of the zinc precursor solution is 0.05-0.2M; the alcoholic solution is ethanol and / or methanol.

[0020] Preferably, in step 4), the heat treatment temperature is 450–650°C, the time is 2–6 h, and the heating rate is 1–2°C / min.

[0021] This invention also provides an antibacterial and osteopromoting agent of zinc-doped mesoporous silica nanoparticles prepared by the aforementioned method, wherein the zinc-doped mesoporous silica nanoparticles have an average particle size of 80–200 nm, an average pore size of 2–5 nm, and a specific surface area of ​​150–350 m². 2 / g;

[0022] The zinc component is dispersed in the framework region, pore wall region and / or particle surface region of the mesoporous silica particles.

[0023] The framework region refers to the silicon-oxygen tetrahedral framework that constitutes the main network of mesoporous silicon particles; the pore wall region refers to the thin layer about 1-2 nm below the inner surface of the mesoporous channel; and the particle surface region refers to the area within about 5 nm of the outermost surface of the particle.

[0024] Preferably, the osteogenic preparation further includes an active component loaded in mesoporous channels, the active component being selected from one or more of antibacterial agents, osteogenic active components, and anti-inflammatory components, the active component loading being 5-35 wt%, and the encapsulation rate being 60-95%.

[0025] Preferably, the antibacterial agent is selected from one or more of vancomycin, gentamicin, levofloxacin, polymyxin, and antimicrobial peptides;

[0026] The osteogenic active component is selected from one or more of dexamethasone, vitamin D derivatives, bone morphogenetic protein mimic peptides, dextran sulfate, and peptide osteogenic promoters.

[0027] The anti-inflammatory component is selected from one or more of dexamethasone, ibuprofen, celecoxib, indomethacin, diclofenac sodium, naproxen, curcumin, resveratrol, quercetin, and tripterygium wilfordii.

[0028] Preferably, the osteopromoting formulation further includes a capping layer disposed on the surface of the particles, wherein the capping layer is one or more of an aminated linker layer, an amide bond linker layer, a gelatin layer, a propyneated gelatin layer, a chitosan layer, and a polydopamine layer; wherein the aminated linker layer is formed by modification with 3-aminopropyltrimethoxysilane, and the amide bond linker layer is formed by EDC / NHS coupling.

[0029] The beneficial effects of this invention are:

[0030] 1) The preparation path is clear and the parameters are controllable. This invention introduces zinc precursor in stages during the formation of mesoporous silicon framework, and combines it with subsequent heat treatment, surface modification and loading of active components to construct a preparation process with clear layers. This makes it easy to control the dispersion state of zinc components, pore structure and surface chemical environment, and the process has good repeatability.

[0031] 2) Balancing zinc doping and mesoporous structure preservation, this invention employs a suitable template method and heat treatment conditions to remove the template agent while preserving the pore structure and specific surface area of ​​the mesoporous silicon particles as much as possible. This ensures that the particles have a good carrier foundation and can provide sufficient pore volume and mass transfer channels for subsequent loading of active components.

[0032] 3) It is beneficial for high drug loading and composite loading. This invention can not only load one or more of antibacterial agents, osteogenic active components or anti-inflammatory components in mesoporous channels, but also achieve orifice control through surface end capping layer, thereby improving the loading stability of active components and reducing unexpected leakage of formulations during storage and use.

[0033] 4) It facilitates multifunctional synergy. This invention combines zinc-doped structure, mesoporous drug-carrying structure and surface-capped structure, enabling the formulation to simultaneously carry antibacterial, osteogenic and anti-inflammatory components. It is suitable for application scenarios with high functional requirements for bone repair materials and logically meets the need for multi-factor synergistic intervention in the bone tissue repair process.

[0034] 5) The structure is flexible and has a wide range of applications. The active components in this invention can be selected as single or multi-component combinations as needed, and the end capping layer can also be flexibly set according to the drug loading object and the application scenario. Therefore, it has good scalability and implementation adaptability, which makes it easy to adjust the scheme for different bone repair scenarios in the future. Attached Figure Description

[0035] Figure 1 Transmission electron microscopy (TEM) images of the zinc-doped mesoporous silicon nanoparticles (Zn-MSN) prepared in Example 1 and the particles in Comparative Example 1.

[0036] Figure 2 This is a STEM-EDS elemental distribution map of the zinc-doped mesoporous silicon nanoparticles obtained in Example 1;

[0037] Figure 3 The X-ray diffraction (XRD) patterns of the particles obtained in Example 1, Comparative Example 1, and Comparative Example 4 are shown below.

[0038] Figure 4 The N2 adsorption-desorption isotherms and pore size distribution curves of the particles obtained in Example 1 and Comparative Example 2 are shown.

[0039] Figure 5 Fourier transform infrared (FTIR) spectra of Zn-MSN particles before and after amination modification and end-capping layer construction;

[0040] Figure 6 The in vitro cumulative release curves of active components under different end-capping systems are shown.

[0041] Figure 7 The antibacterial effects of Examples 1, 2, and 3 against Staphylococcus aureus and Escherichia coli are shown in the figures.

[0042] Figure 8 The graph shows the detection results of the effects of Example 1 and Comparative Example 3 on osteogenic related indicators. Detailed Implementation

[0043] The present invention will be further described below through specific embodiments. To make the inventive objectives, technical solutions, and beneficial technical effects of the present invention clearer, the present invention will be further described in detail below with reference to the embodiments. It should be understood that the embodiments described in this specification are merely for explaining the present invention and are not intended to limit the present invention.

[0044] Unless otherwise stated, all instruments and reagents used in the examples are commercially available or synthesized using conventional methods and can be used directly without further processing, and all instruments used in the examples are commercially available.

[0045] Example 1: Preparation of zinc-doped mesoporous silicon nanoparticles and co-loading with vancomycin / dexamethasone

[0046] 1. Preparation of Zinc-Doped Mesoporous Silicon Nanoparticles (Zn-MSN)

[0047] Dissolve 0.50 g of cetyltrimethylammonium bromide (CTAB) in a mixed solvent of 240 mL deionized water and 60 mL anhydrous ethanol. Heat to 70 °C and stir at 700 rpm until completely dissolved. Adjust the pH of the system to 8.5 using 0.1 M NaOH solution. Add 5.0 g of tetraethyl orthosilicate (TEOS, CTAB to TEOS mass ratio approximately 1:10) and start timing.

[0048] 35 minutes after the addition of TEOS, the first zinc precursor solution was slowly added dropwise using a constant pressure dropping funnel: 0.079 g of zinc acetate dihydrate (corresponding to 1.5 mol% of TEOS in Zn) was dissolved in 3.6 mL of anhydrous ethanol to prepare an approximately 0.1 M zinc acetate ethanol solution, and the addition time was controlled within 10 minutes.

[0049] After continuing the reaction for 75 min, the second zinc precursor solution was added dropwise: 0.237 g of zinc acetate dihydrate (to make the total molar percentage of zinc component reach 6 mol%) was dissolved in 10.8 mL of anhydrous ethanol and added slowly dropwise at a concentration of 0.1 M over a period of 15 min.

[0050] After the second batch of zinc precursor was added, the reaction was stirred for another 2 hours, and then the system was transferred to a water bath for aging for 12 hours. After aging, the product was collected by centrifugation at 8000 rpm for 10 minutes, washed three times each with deionized water and anhydrous ethanol, and dried in a vacuum drying oven at 60°C for 12 hours to obtain zinc-doped mesoporous silicon precursor particles.

[0051] The dried precursor particles were placed in a tube furnace and heated to 550°C at a heating rate of 1.5°C / min. The temperature was held for calcination for 4 hours, and then naturally cooled to obtain zinc-doped mesoporous silicon nanoparticles (Zn-MSN).

[0052] 2. Characterization Results

[0053] Morphology and particle size: Transmission electron microscopy (TEM) showed that the particles were spherical with an average particle size of about 120 nm, uniformly distributed, and without obvious agglomeration.

[0054] Pore ​​structure: The N2 adsorption-desorption isotherm shows a typical type IV isotherm, with a BET specific surface area of ​​approximately 280 m². 2 / g, the average pore size calculated by the BJH method is approximately 3.5nm.

[0055] Zinc distribution: STEM-EDS elemental surface scanning showed that Zn, Si, and O elements were uniformly distributed in the particles; X-ray photoelectron spectroscopy (XPS) detected Zn 2p at 1022.5 eV. 3 / 2 peak.

[0056] Phase composition: The XRD pattern showed mesoporous characteristic diffraction peaks (100) in the range of 2θ = 2–10°, and no obvious ZnO characteristic diffraction peaks (31.7°, 34.4°, 36.2°) were observed, indicating that the zinc component exists in a highly dispersed state in the framework region, pore wall region and particle surface region, and has not formed an independent crystalline phase.

[0057] Zinc content: ICP-OES analysis showed that the Zn / Si molar ratio in the particles was approximately 0.056, which is basically consistent with the theoretical feed rate (6 mol%).

[0058] 3. Surface amination modification

[0059] 1.0 g of the above Zn-MSN was dispersed in 80 mL of anhydrous toluene and ultrasonically dispersed for 30 min. Then, 2.0 mL of 3-aminopropyltrimethoxysilane (APTES) was added, and the mixture was refluxed under nitrogen protection for 12 h. After the reaction was completed, the mixture was collected by centrifugation, washed three times with ethanol, and dried under vacuum at 60 °C to obtain amino-doped zinc mesoporous silica nanoparticles (NH2-Zn-MSN).

[0060] 4. Loading of active components

[0061] Preparation of the active ingredient loading solution: Dissolve 0.20 g vancomycin hydrochloride (antibacterial agent) and 0.05 g dexamethasone (osteogenic active ingredient) in 30 mL of PBS / ethanol mixed solvent (volume ratio 1:1), add 1.0 g NH2-Zn-MSN, and stir at room temperature in the dark for 24 h. Centrifuge to collect the solid, freeze-dry to obtain drug-loaded particles.

[0062] Drug loading determination: The concentration of the remaining drug in the supernatant was determined by ultraviolet-visible spectrophotometry, and the total active component loading was calculated to be approximately 20 wt%, with an encapsulation efficiency of approximately 82%.

[0063] 5. Endcap layer construction

[0064] The drug-loaded particles were dispersed in 50 mL of 0.5 wt% chitosan-acetic acid solution (acetic acid concentration 1 v / v%) and stirred at room temperature for 4 h to allow chitosan to coat the particle surface through electrostatic interaction, forming a capping layer. After centrifugation, washing, and freeze-drying, the final formulation (Zn-MSN / Van-Dex@CS) was obtained.

[0065] 6. Evaluation of in vitro antibacterial and osteogenic activity

[0066] Antibacterial properties: The antibacterial effect against Staphylococcus aureus was evaluated using the plate count method. After co-incubating the formulation with the bacterial suspension for 4 hours, the antibacterial rate was >99%, indicating that zinc ions and vancomycin have a synergistic antibacterial effect.

[0067] Osteogenic performance: The extract of the preparation was co-cultured with MG63 cells. On day 7, ALP activity was approximately 2.3 times higher than that of the pure MSN control group; on day 21, Alizarin Red staining showed a significant increase in the number of mineralized nodules, indicating that the release of zinc components effectively promoted osteogenic differentiation.

[0068] Example 2: High zinc content and zinc nitrate methanol solution system

[0069] 1. Preparation of Zn-MSN

[0070] The amount of CTAB used was 0.50g, and the amount of TEOS was 4.0g (the mass ratio of CTAB to TEOS was approximately 1:8). The reaction temperature was 80 ℃, the pH was 9.0, and the stirring speed was 1000 rpm.

[0071] The first zinc precursor: 30 min after the silicon source was added, a methanol solution of zinc nitrate hexahydrate (0.15 M, containing 3 mol% of TEOS of Zn) was added dropwise.

[0072] 60 minutes after the first addition, add the second portion of zinc nitrate hexahydrate methanol solution (0.15M) dropwise to bring the total molar percentage of zinc to 8 mol.

[0073] After aging, washing, and drying, the mixture is calcined at 650℃ for 2 hours with a temperature increase of 1℃ / min.

[0074] 2. Characterization Results

[0075] The average particle size is approximately 150 nm, and the specific surface area is approximately 200 m². 2 / g, with an average pore size of approximately 2.8nm.

[0076] XRD showed that the mesoporous structure remained intact, with no obvious ZnO crystal phase diffraction peaks.

[0077] ICP-OES analysis showed that the Zn / Si molar ratio was approximately 0.074.

[0078] 3. Loading and capping of active components

[0079] Active components: Gentamicin sulfate (antibacterial agent) and bone morphogenetic protein mimetic peptide (BMP-2 mimetic peptide, osteogenic active component).

[0080] The loading solution was PBS buffer, and the mixture was stirred at room temperature for 18 hours.

[0081] The load capacity is approximately 28 wt%, and the encapsulation rate is approximately 75%.

[0082] End-capping layer: Polydopamine (PDA). Drug-loaded particles were dispersed in Tris-HCl buffer at pH 8.5, and dopamine hydrochloride (2 mg / mL) was added. The mixture was stirred at room temperature for 3 h to form a polydopamine end-capping layer on the particle surface through self-assembly.

[0083] 4. Activity Evaluation

[0084] It exhibits significant antibacterial activity against both Escherichia coli (E. coli) and S. aureus.

[0085] Co-culture with BMSCs for 14 days resulted in an approximately 1.8-fold increase in the expression levels of osteogenic markers RUNX2 and COL-I compared to control group 3 (zinc-free).

[0086] Example 3: Low zinc content, low temperature heat treatment and amide bond bonding layer end capping

[0087] 1. Preparation of Zn-MSN

[0088] CTAB 0.50g, TEOS 6.0g (CTAB to TEOS mass ratio approximately 1:12), reaction temperature 60℃, pH 8.0, stirring speed 500rpm.

[0089] The first zinc precursor: 45 min after the silicon source was added, zinc acetate ethanol solution (0.05 M, containing 1 mol% of TEOS of Zn) was added dropwise.

[0090] 90 minutes after the first addition, add the second zinc acetate ethanol solution (0.05M) dropwise to bring the total molar percentage of zinc to 4 mol.

[0091] After aging, washing, and drying, the mixture is calcined at 450℃ for 6 hours with a temperature increase of 2℃ / min.

[0092] 2. Characterization Results

[0093] The average particle size is approximately 90 nm, and the specific surface area is approximately 320 m². 2 / g, with an average pore size of approximately 4.2nm.

[0094] The particles are monodisperse and have a high degree of mesoporous order.

[0095] 3. Surface modification and drug loading

[0096] First, amination is performed (same as in Example 1).

[0097] Active ingredients: Levofloxacin (antibacterial agent) and 1α,25-dihydroxyvitamin D3 (vitamin D derivative, osteogenic active ingredient).

[0098] The load capacity is 12 wt%, and the encapsulation rate is 88%.

[0099] 4. Construction of the end-capping layer (amide bond linking layer)

[0100] Aminated drug-loaded particles were dispersed in MES buffer (pH 6.0), and 0.5 g of gelatin and coupling agent EDC / NHS (molar ratio 1:1:2, gelatin:EDC:NHS) were added. The mixture was stirred at room temperature for 6 h to allow the gelatin to be covalently linked to the particle surface via amide bonds. After centrifugation, washing, and freeze-drying, the particles were then removed.

[0101] The resulting formulation exhibits sustained-release characteristics in PBS, with a burst release of <15% within 24 hours and a cumulative release of approximately 65% ​​over 14 days.

[0102] Example 4: Propylene gelatin end-capping and polymyxin loading

[0103] 1. Preparation of Zn-MSN

[0104] The process was basically the same as in Example 1, with a total zinc molar percentage of 5 mol% (2 mol% in the first batch and 5 mol% in subsequent batches). The heat treatment conditions were 600°C for 3 hours and a heating rate of 1.2°C / min.

[0105] 2. Characterization Results

[0106] The average particle size is approximately 110 nm, and the specific surface area is approximately 250 m². 2 / g, with an average pore size of approximately 3.2nm.

[0107] 3. Loading of active components

[0108] The loading fluid contains polymyxin B (an antibacterial agent) and dextran sulfate (an osteogenic active component), with a loading of approximately 8 wt% and an encapsulation rate of 79%.

[0109] 4. Construction of the end-capping layer (propynized gelatin layer)

[0110] Gelatin propyne modification: 1.0 g gelatin was dissolved in 50 mL PBS, 0.5 g 4-pentynic acid was added, and the mixture was activated and coupled with EDC / NHS. The reaction was carried out at room temperature for 12 h, and the gelatin was obtained by lyophilization after dialyzing.

[0111] Drug-loaded particles were dispersed in a propynylated gelatin aqueous solution (2 wt%) and stirred at room temperature for 4 h. The propynylated gelatin end-capping layer was formed on the particle surface through physical adsorption and hydrogen bonding.

[0112] 5. Activity Evaluation

[0113] It exhibits significant antibacterial activity against Pseudomonas aeruginosa; when co-cultured with MC3T3-E1 cells, the OCN expression level on day 14 was 2.1 times higher than that in the control group.

[0114] Example 5: Low-load rapid release system

[0115] 1. Preparation of Zn-MSN

[0116] Same as in Example 1, the total molar percentage of zinc is 7 mol% (2.5 mol% in the first part, and 7 mol% in the second part).

[0117] 2. Loading of active components

[0118] The loading solution contains antimicrobial peptides (LL-37 analog, antimicrobial agent) and peptide osteogenic promoters (such as BMP-7 active peptide fragment), with a loading of 8 wt% and an encapsulation rate of 65%.

[0119] 3. End cap layer

[0120] An amide bond connecting layer coupled with EDC / NHS is used: Aminated drug-loaded particles are reacted with carboxymethyl chitosan under EDC / NHS activation to form an amide bond-connected chitosan end-capping layer.

[0121] 4. Release behavior

[0122] The formulation releases approximately 40% of its active components within the first 48 hours, making it suitable for early postoperative anti-infection and rapid osteogenic induction needs.

[0123] Example 6: Anti-inflammatory component loaded separately and system without additional end-capping layer

[0124] 1. Preparation of Zn-MSN

[0125] Same as Example 1 (total zinc molar percentage 6 mol, heat treatment 550°C).

[0126] 2. Surface amination modification

[0127] Following the same procedure as in Example 1 (APTES / toluene reflow), aminated zinc-doped mesoporous silicon nanoparticles (NH2-Zn-MSN) were obtained. This aminated layer serves as the final capping layer, without any further coating of other materials.

[0128] 3. Loading of active ingredients (anti-inflammatory components)

[0129] 1.0 g of NH2-Zn-MSN was dispersed in 30 mL of anhydrous ethanol, and 0.15 g of ibuprofen was added. The mixture was stirred at room temperature in the dark for 24 h. After centrifugation, the mixture was collected and dried under vacuum at 40 °C to obtain the ibuprofen-supported Zn-MSN formulation.

[0130] Drug loading: 14.2 wt%, encapsulation efficiency: 91.3% (determined by UV-Vis spectrophotometry).

[0131] Example 7: Co-loading system of antibacterial agent + osteogenic active component + anti-inflammatory component

[0132] 1. Preparation of Zn-MSN

[0133] Same as Example 2 (total zinc molar percentage 8 mol, zinc nitrate methanol system, heat treatment at 650°C).

[0134] 2. Surface finishing and co-loading of the three components

[0135] Take 1.0 g of the above Zn-MSN and perform amination modification as in Example 1. Prepare a mixed loading solution: 30 mL PBS / ethanol (1:1), containing vancomycin (antibacterial agent, 0.12 g), dexamethasone (osteogenic active component, 0.03 g), and celecoxib (anti-inflammatory component, 0.05 g). Add the amination particles and stir at room temperature for 24 h. Centrifuge and freeze-dry.

[0136] Drug loading calculation: The total active ingredient loading is approximately 26.8 wt%, with encapsulation efficiencies of 72% (vancomycin), 81% (dexamethasone), and 68% (celecoxib), respectively.

[0137] 3. End cap layer

[0138] Similar to Example 3, an amide bond connecting layer formed by EDC / NHS coupled gelatin was used as the end cap.

[0139] Comparative Example 1: Zinc precursor added in one step (not in stages)

[0140] The preparation process is the same as in Example 1, except that: all zinc precursor (zinc acetate ethanol solution, total Zn 6mol%) is added at once 30 min after the addition of TEOS, and no further additions are made.

[0141] Results: TEM showed a broadened particle size distribution (60–250 nm), with some particles exhibiting significant agglomeration; the BET specific surface area decreased to approximately 180 m² / g; XRD revealed weak ZnO diffraction peaks at 31.7° and 36.2°, indicating uneven zinc distribution and local enrichment to form zinc oxide microcrystals. The drug loading and encapsulation efficiency decreased to approximately 55%.

[0142] Conclusion: Stepwise addition plays a crucial role in maintaining the monodispersity of the particles and preventing zinc phase separation.

[0143] Comparative Example 2: Zinc precursor was added in the form of an aqueous solution

[0144] The preparation process is the same as in Example 1, except that both zinc precursors are added dropwise in the form of an aqueous solution (0.1M zinc acetate aqueous solution) instead of an ethanol solution.

[0145] Results: A white flocculent precipitate (Zn(OH)2) immediately appeared during the dropwise addition process. TEM analysis of the product after centrifugation showed that a large number of irregular precipitates were attached to the particle surface, the pore structure was partially blocked, and the BET specific surface area was only about 95 m². 2 / g. Drug loading <5wt%, almost no sustained-release effect.

[0146] Conclusion: Using an alcohol solution as the zinc precursor is key to avoiding hydroxide precipitation under alkaline conditions and maintaining the integrity of the mesoporous structure.

[0147] Comparative Example 3: Pure mesoporous silicon nanoparticles (MSN) without zinc doping

[0148] The preparation process is the same as in Example 1, but no zinc precursor is added throughout the process.

[0149] Results: The average particle size was approximately 100 nm, and the specific surface area was approximately 450 m². 2 / g, pore size approximately 3.0nm. After loading vancomycin / dexamethasone, the loading capacity is 22wt%, and the encapsulation efficiency is 85%.

[0150] Activity evaluation:

[0151] Antibacterial: No significant antibacterial effect against S. aureus (antibacterial rate <10%).

[0152] Osteogenesis: After co-culturing with MG63 for 14 days, ALP activity and the number of mineralized nodules were significantly lower than in Example 1 (approximately 45% of the former).

[0153] Conclusion: The introduction of zinc components is a necessary condition for endowing the formulation with inherent antibacterial activity and enhancing its osteogenic effect.

[0154] Comparative Example 4: Outside the pH range (pH 10.5)

[0155] The preparation process is the same as in Example 1, except that the pH of the system is adjusted to 10.5.

[0156] Results: Even when using an ethanol solution to add the zinc precursor dropwise, slight turbidity still appeared after the addition of the second zinc sample; the final product had a BET specific surface area of ​​approximately 160 m². 2 / g, pore size distribution broadened; XRD detected obvious ZnO characteristic peaks. Drug loading and encapsulation efficiency was approximately 58%.

[0157] Conclusion: pH 8.0–9.5 is the suitable range for the formation of equilibrium mesoporous structures and the stable dispersion of zinc components.

[0158] To verify the effects of different zinc introduction methods and reaction conditions on the formation of mesoporous structures, the particle size distribution, specific surface area and crystal phase structure of the particles obtained in Example 1 and Comparative Examples 1, 2 and 4 were tested. The results are shown in Table 1.

[0159] Table 1. Structural characterization results of Zn-MSN particles under different process conditions

[0160] Example 1 Step by step ethanol 8.5 uniform 280 none Comparative Example 1 once ethanol 8.5 Broadening 180 weak Comparative Example 2 Step by step water 8.5 Reunion 95 powerful Comparative Example 4 Step by step ethanol 10.5 Inequality 160 obvious

[0161] The results showed that when zinc precursor was added in stages and the pH of the system was controlled in the range of 8.0 to 9.5, the resulting particles had a more uniform particle size distribution and a more complete mesoporous structure, and no obvious ZnO crystal phase was observed. However, adding zinc precursor all at once, adding zinc precursor in aqueous solution, or increasing the pH of the system all led to particle agglomeration, a decrease in specific surface area, and local precipitation of ZnO.

[0162] To verify the comprehensive performance of the formulation of the present invention in terms of antibacterial and osteogenic properties, in vitro antibacterial and osteogenic related experiments were conducted on Examples 1, 2, and 3. The results are shown in Table 2.

[0163] Table 2 Overall biological performance

[0164] Example 1 >99% 2.3× 2.0× powerful Example 2 >99% 1.8× 1.8× powerful Comparative Example 3 <10% 1.0× 1.0× weak

[0165] The results showed that after doping with zinc, the formulation exhibited a high inhibition rate against Staphylococcus aureus and Escherichia coli, and could also improve ALP activity, RUNX2 expression level and mineralized nodule formation ability; while the pure MSN system without zinc doping had a certain drug loading capacity, but lacked obvious antibacterial activity and osteogenic promoting effect.

[0166] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for preparing an antibacterial and osteopromoting agent using zinc-doped mesoporous silica nanoparticles, characterized in that, The steps include the following: 1) Mesoporous silica nanoparticle precursors were prepared using a template method; 2) During the hydrolysis and condensation process of the silicon source, zinc precursor is added in stages to disperse the zinc component in the framework region and pore wall region of the mesoporous silicon particles. 3) The obtained system was aged, centrifuged, collected, washed and dried to obtain zinc-doped mesoporous silicon precursor particles; 4) The precursor particles are subjected to heat treatment to remove the template agent, thereby obtaining zinc-doped mesoporous silicon nanoparticles; 5) The obtained particles were surface modified and loaded with active components to obtain a zinc-doped mesoporous silicon nanoparticle antibacterial and osteopromoting agent.

2. The method for preparing a zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent according to claim 1, characterized in that, The template agent mentioned in step 1) is hexadecyltrimethylammonium bromide, the silicon source is tetraethyl orthosilicate, the mass ratio of template agent to tetraethyl orthosilicate is 1:8 to 1:12, the pH of the reaction system is 8.0 to 9.5, the reaction temperature is 60 to 80°C, and the stirring rate is 500 to 1000 rpm.

3. The method for preparing a zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent according to claim 1, characterized in that, In step 2), the first zinc precursor solution is added 30 to 45 minutes after the silicon source is added, and the second zinc precursor solution is added 60 to 90 minutes after the first zinc precursor solution is added.

4. The method for preparing a zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent according to claim 3, characterized in that, In step 2), the zinc component in the first zinc precursor solution is 1-3 mol, and the total molar percentage of zinc component after the addition of the second zinc precursor solution is 4-8 mol.

5. The method for preparing a zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent according to claim 2, characterized in that, The zinc precursor is an alcoholic solution of zinc acetate and / or zinc nitrate, with a concentration of 0.05–0.2 M; the alcoholic solution is ethanol and / or methanol.

6. The method for preparing a zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent according to claim 1, characterized in that, Step 4) The heat treatment temperature is 450-650℃, the time is 2-6h, and the heating rate is 1-2℃ / min.

7. A zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent prepared by the preparation method according to any one of claims 1 to 6, characterized in that, The zinc-doped mesoporous silicon nanoparticles have an average particle size of 80–200 nm, an average pore size of 2–5 nm, and a specific surface area of ​​150–350 m². 2 / g; The zinc component is dispersed in the framework region, pore wall region and / or particle surface region of the mesoporous silica particles.

8. The zinc-doped mesoporous silicon nanoparticle antibacterial and osteopromoting agent according to claim 7, characterized in that, The osteogenic preparation further includes an active component loaded in mesoporous channels. The active component is selected from one or more of antibacterial agents, osteogenic active components, and anti-inflammatory components. The loading of the active component is 5-35 wt%, and the encapsulation rate is 60-95%.

9. The zinc-doped mesoporous silica nanoparticle antibacterial and osteopromoting agent according to claim 8, characterized in that, The antibacterial agent is selected from one or more of vancomycin, gentamicin, levofloxacin, polymyxin, and antimicrobial peptides. The osteogenic active component is selected from one or more of dexamethasone, vitamin D derivatives, bone morphogenetic protein mimic peptides, dextran sulfate, and peptide osteogenic promoters. The anti-inflammatory component is selected from one or more of dexamethasone, ibuprofen, celecoxib, indomethacin, diclofenac sodium, naproxen, curcumin, resveratrol, quercetin, and tripterygium wilfordii.

10. The zinc-doped mesoporous silicon nanoparticle antibacterial and osteopromoting agent according to claim 8, characterized in that, The osteogenic preparation further includes a capping layer disposed on the surface of the particles. The capping layer is one or more of the following: an aminated linking layer, an amide bond linking layer, a gelatin layer, a propyneated gelatin layer, a chitosan layer, and a polydopamine layer. The aminated linking layer is formed by modification with 3-aminopropyltrimethoxysilane, and the amide bond linking layer is formed by EDC / NHS coupling.